Vialize TM
VializeRenderingNew

A lyophilized complete human placental membrane allograft

Vialize is a lyophilized dehydrated complete human placental membrane (dCHPM) allograftA tissue graft from a donor of the same species as the recipient but not genetically identical.1 designed for homologous use as a wound covering or barrier membrane.  Through our patented preservation process, Clearify, Vialize preserves all three layers of the native tissue, maximizing the concentration of components naturally found in the tissue.2,3

Product Features & Benefits

Protective and resorbableGradually breaks down and absorbs naturally into the body1 barrier membrane2
Excellent product handling and suture-ability2
Complete, shelf-stable wound covering
4x thicker than the leading competitor2

Why is Vialize unique?

The use of placental tissues in wound care has been documented in medical texts since the early 20th century.4 There are three distinct layers that make up this membrane: the amnion layerThe amnion layer is the innermost layer of the placental membrane. This layer provides tensile strength and acts as a fibrous skeleton.3, intermediate layerThe intermediate layer exists between the amnion and chorion layers and is rich in collagens, proteoglycans, and glycosaminoglycans, like hyaluronic acid.3, and chorion layerThe chorion layer is the outermost, thickest layer of the placental membrane. It contributes to elasticity and membrane stability.3.The three layers function together to create the ideal protective covering and barrier between the mother and the fetus.

While most placental membrane-based products provide single or dual layer allografts, StimLabs has developed the first membrane allograft to retain all three layers of the membrane, including the intermediate layer.2 The preserved intermediate layer is a vital part of the membrane barrier property intrinsic to the tissue. The layer contributes to the overall composition of the allograft, containing extracellular matrix components like collagenProvides strength and structural resistance to degrading enzymes in native placental tissue.3, proteoglycansPromotes tissue hydration in native placental tissue.3, and glycosaminoglycans, like hyaluronic acidProvides lubricating and elastic properties in native placental tissue.3.3

Where is Vialize commonly applied?

Specialties include:

  • Plastic Surgery
  • Vascular Surgery
  • General Surgery
  • Infectious Disease
  • Podiatry
  • Orthopedics
  • OBGYN
  • Urology
  • Spine
clearify-logo-homepage

How do we retain these components?

Clearify is a unique, patented processing approach to placental tissue that maximizes the retention of desired structural components, while effectively cleaning and terminally sterilizing the graft. 2 The Clearify processing method is designed to preserve all three layers of the placental membrane. 2 The Vialize allografts are freeze-dried and never delaminated, meaning that in processing, the layers aren’t pulled apart. This process preserves key structural components and the natural architectural features from being stripped away or damaged.2

Vialize Mockup

Product Information

Sheet format   |   Shelf-stable for up to five (5) years

Sizes   |   2x3 cm, 4x4 cm, 4x6 cm, 6x8 cm, 2x12 cm

Product Codes    |    VL-2030, VL-4040, VL-4060, VL-6080, VL-0212

product-info-icon

For more application and use information, please see the Instructions for Use.

  1. Oxford Languages. (n.d.). Oxford Advanced Learner’s Dictionary. Retrieved March 01, 2022, from https://languages.oup.com/google-dictionary-en/.
  2. Data on file. The data is reported as an average.
  3. Roy, A., & Griffiths, S. (2020). Intermediate Layer Contribution in Placental Membrane Allografts. Journal of Tissue Engineering and Regenerative Medicine14(8), 1126–1135. https://doi.org/10.1002/term.3086.
  4. Silini, A. R., Cargnoni, A., Magatti, M., Pianta, S., & Parolini, O. (2015). The Long Path of Human Placenta, and Its Derivatives, in Regenerative Medicine. Frontiers in Bioengineering and Biotechnology3(162). https://doi.org/10.3389/fbioe.2015.00162.